Product nameAnti-FGF10 antibody
See all FGF10 primary antibodies
DescriptionRabbit polyclonal to FGF10
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Predicted to work with: Rat, Sheep, Non human primates
Synthetic peptide corresponding to Human FGF10 aa 150 to the C-terminus (C terminal) conjugated to keyhole limpet haemocyanin.
(Peptide available as
- This antibody gave a positive signal in Human lung tissue lysate and A549 whole cell lysate.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.02% Sodium Azide
Constituents: 1% BSA, PBS, pH 7.4
Concentration information loading...
PurityImmunogen affinity purified
Immunizing Peptide (Blocking)
Our Abpromise guarantee covers the use of ab91024 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 µg/ml. Detects a band of approximately 37 kDa (predicted molecular weight: 23 kDa).|
FunctionCould be a growth factor active in the process of wound healing. Acts as a mitogen in the lung. May act in a manner similar to FGF-7.
Involvement in diseaseDefects in FGF10 are the cause of autosomal dominant aplasia of lacrimal and salivary glands (ALSG) [MIM:180920]. ALSG has variable expressivity, and affected individuals may have aplasia or hypoplasia of the lacrimal, parotid, submandibular and sublingual glands and absence of the lacrimal puncta. The disorder is characterized by irritable eyes, recurrent eye infections, epiphora (constant tearing) and xerostomia (dryness of the mouth), which increases the risk of dental erosion, dental caries, periodontal disease and oral infections.
Defects in FGF10 are a cause of lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:149730]; also known as Levy-Hollister syndrome. LADDS is a form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. LADDS is an autosomal dominant syndrome characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.
Sequence similaritiesBelongs to the heparin-binding growth factors family.
- Information by UniProt
- BB213776 antibody
- fd11d03 antibody
- FGF 10 antibody
All lanes : Anti-FGF10 antibody (ab91024) at 1 µg/ml
Lane 1 : Lung (Human) Tissue Lysate
Lane 2 : A549 (Human lung adenocarcinoma epithelial cell line) Whole Cell Lysate
Lysates/proteins at 10 µg per lane.
All lanes : Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 23 kDa
Observed band size: 37 kDa why is the actual band size different from the predicted?
Additional bands at: 160 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 3 minutes
FGF10 contains a number of potential glycosylation sites (SwissProt) which may explain its migration at a higher molecular weight than predicted. Furthermore, the 37 kDa band observed is comparable to the molecular weight seen with other commercially available antibodies to FGF10.
ab91024 has not yet been referenced specifically in any publications.